("InnovaDerma" or the "Company")
InnovaDerma (LSE: IDP), a UK developer of life sciences, beauty and personal care products, announces that it was notified today, that Joseph Bayer, Executive Chairman of the Company, has purchased 3,000 Ordinary Shares of €0.10 each in the Company at a price of 62.00 pence per Ordinary Share (the "Acquisition") which will be held via his Australian Superannuation Fund which Mr Bayer controls. He now holds 129,000 Ordinary Shares in the Company via his Australian Superannuation Fund.
Following the Acquisition, Joseph Bayer has, through direct and indirect holdings, a total interest in the Company of 161,840 Ordinary Shares representing approximately 1.12% of the issued share capital of the Company.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Kieran Callan c/o TB Cardew
+61 (0)3 9863 8030
+44 (0)20 7930 0777
Geoff Nash/ Kate Bannatyne
Alice Lane/Manasa Patil - Corporate Broking
+44 (0)207 220 0500
Shan Shan Willenbrock/Tom Allison
+ 44 (0)20 7930 0777
Details of the person discharging managerial responsibilities / person closely associated
Reason for the Notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the Financial instrument, type of instrument
€0.10 each ("Ordinary Shares")
Nature of the transaction
Purchase of Ordinary Shares
Price(s) and volume(s)
Volume and Price -3,000 Ordinary Shares at 62 pence per share
See 4c) above
Date of the transaction
29 November 2019
Place of the transaction
London Stock Exchange, Main Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.